相似文献
1
Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks.
Antimicrob Agents Chemother. 2005 Oct;49(10):4396-9. doi: 10.1128/AAC.49.10.4396-4399.2005.
2
Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).
Hepatology. 2001 Jan;33(1):254-66. doi: 10.1053/jhep.2001.20899.
3
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8. doi: 10.1128/AAC.49.7.2720-2728.2005.
4
Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus.
Virology. 2004 Sep 15;327(1):26-40. doi: 10.1016/j.virol.2004.06.017.
5
Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.
Antimicrob Agents Chemother. 2004 Jul;48(7):2683-92. doi: 10.1128/AAC.48.7.2683-2692.2004.
6
Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent.
Antivir Ther. 1998;3(Suppl 3):113-21.
7
8
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Hepatology. 2021 Jan;73(1):53-67. doi: 10.1002/hep.31255. Epub 2020 Nov 27.
9
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Antimicrob Agents Chemother. 2001 Apr;45(4):1065-77. doi: 10.1128/AAC.45.4.1065-1077.2001.
10
Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.
J Virol. 2007 Oct;81(19):10614-24. doi: 10.1128/JVI.00691-07. Epub 2007 Jul 25.
引用本文的文献
1
Mirror-Image Oligonucleotides: History and Emerging Applications.
Chemistry. 2019 Jun 18;25(34):7981-7990. doi: 10.1002/chem.201900149. Epub 2019 Apr 26.
2
Therapy of Delta Hepatitis.
Cold Spring Harb Perspect Med. 2015 Aug 7;5(10):a021543. doi: 10.1101/cshperspect.a021543.
3
Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles.
J Virol. 2014 May;88(10):5742-54. doi: 10.1128/JVI.00430-14. Epub 2014 Mar 12.
4
Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.
Lab Invest. 2014 Feb;94(2):120-8. doi: 10.1038/labinvest.2013.142. Epub 2013 Dec 16.
5
Molecular and clinical aspects of hepatitis D virus infections.
World J Virol. 2012 Jun 12;1(3):71-8. doi: 10.5501/wjv.v1.i3.71.
6
Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks.
Hepatology. 2012 Jul;56(1):76-85. doi: 10.1002/hep.25663. Epub 2012 Apr 25.
7
Development of mathematical models for the analysis of hepatitis delta virus viral dynamics.
PLoS One. 2010 Sep 16;5(9):e12512. doi: 10.1371/journal.pone.0012512.
8
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40. doi: 10.1038/nrgastro.2009.205.
9
Hepatitis d.
Curr Treat Options Gastroenterol. 2007 Dec;10(6):456-63. doi: 10.1007/s11938-007-0045-8.
10
Antiviral therapy and resistance with hepatitis B virus infection.
World J Gastroenterol. 2007 Jan 7;13(1):125-40. doi: 10.3748/wjg.v13.i1.125.
本文引用的文献
1
Treatment of hepatitis D.
J Viral Hepat. 2005 Jan;12(1):2-9. doi: 10.1111/j.1365-2893.2005.00601.x.
2
3
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.
Hepatology. 2004 Jul;40(1):140-8. doi: 10.1002/hep.20257.
4
Antiviral therapy for hepatitis B virus infections: new targets and technical challenges.
J Clin Virol. 2002 Dec;25(3):267-83. doi: 10.1016/s1386-6532(02)00107-5.
5
Famciclovir treatment of chronic delta hepatitis.
J Hepatol. 2002 Aug;37(2):266-71. doi: 10.1016/s0168-8278(02)00162-9.
6
Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.
J Virol. 2002 Jun;76(11):5305-14. doi: 10.1128/jvi.76.11.5305-5314.2002.
7
Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).
Hepatology. 2001 Jan;33(1):254-66. doi: 10.1053/jhep.2001.20899.
8
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.
J Virol. 2001 Jan;75(1):311-22. doi: 10.1128/JVI.75.1.311-322.2001.
9
Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.
J Viral Hepat. 2000 Nov;7(6):428-34. doi: 10.1046/j.1365-2893.2000.00254.x.
10
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans.
Hepatology. 2000 May;31(5):1165-75. doi: 10.1053/he.2000.5982.
Zotero 插件